A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Inclusion Criteria:

• Physician-diagnosed asthma who have received a physician-prescribed asthmacontroller medication for at least 12 months prior to screening visit.

• Participants must have an asthma control questionnaire-6 (ACQ-6) score of ≥1.5 on 2out of 3 visits before randomization.

• History of 1 severe asthma exacerbation that led to systemic glucocorticoidtreatment in the last 12 months prior to screening visit.

Exclusion Criteria:

• Participants are excluded from the study if any of the following criteria apply:

• An established diagnosis of occupational asthma

• Known pre-existing, clinically important lung condition other than asthma, includingbut not limited to:

• chronic respiratory infection

• bronchiectasis

• pulmonary fibrosis

• allergic bronchopulmonary aspergillosis

• emphysema

• chronic bronchitis

• eosinophilic granulomatosis with polyangiitis

• chronic obstructive pulmonary disease, and

• other mimics of asthma, that is, vocal cord dysfunction.

• Have a current or recent acute, active infection. For at least 30 days beforescreening visit and up to the randomization visit.